CBD Oil for Mesothelioma? New Case Study Suggests It’s Possible

CBD Oil

The case study of a UK lung cancer patient whose tumor shrunk while she was taking CBD oil could be a hopeful sign for mesothelioma patients, too.  pleural mesothelioma and non-small cell lung cancer are different disease but they share many commonalities. Both affect the lungs and cause similar symptoms. Sometimes, a treatment that works for NSCLC can help mesothelioma patients and vice versa. The subject of the new case study was a lung cancer patient in her 80s. She went to the doctor for a cough that would not go away. A CT scan showed the woman had a tumor in her right lung.  Later, she developed more lung tumors.  The patient decided not to have surgery because of … Continue reading CBD Oil for Mesothelioma? New Case Study Suggests It’s Possible »

Relapsed Mesothelioma Patients Live Longer on Opdivo in Phase 3 Trial

relapsed mesothelioma patients

A multi-center British study suggests that the cancer drug Opdivo (nivolumab) may be a solid second-line treatment option for relapsed mesothelioma patients.  The Phase-3 trial involved mesothelioma patients from 24 UK hospitals. All had an ECOG score of 0 or 1, meaning they were in reasonably good health overall.  All of the patients had first-line treatment with platinum-based chemotherapy. Then their cancer came back. There is no approved treatment for relapsed mesothelioma patients. So these patients enrolled in the nivolumab trial.  Although Opdivo is not a cure for mesothelioma, the results of the news trial show it could extend survival for the right patients.  How Does Opdivo Work? Nivolumab is sold under the brand name Opdivo. It is an immunotherapy … Continue reading Relapsed Mesothelioma Patients Live Longer on Opdivo in Phase 3 Trial »

Asbestos Deaths in Italy Top 4,000 Per Year Decades After Ban

asbestos deaths

Researchers in Italy say there were 4,400 asbestos deaths in the country between 2010 and 2016 – more than two decades after the country banned the substance.  Italy was one of the main European producers of asbestos until the 1992 ban. The new report shows the destructive legacy asbestos can have on a country. Most of the asbestos deaths were from lung cancer or malignant mesothelioma. Some people also died of asbestosis or ovarian cancer. The research team says the numbers “suggest the need for appropriate interventions” to protect people from mesothelioma and other asbestos-related diseases.  Mesothelioma is Not the Only Fatal Asbestos-Related Disease Asbestos is the primary cause of pleural and peritoneal mesothelioma. Mesothelioma is even sometimes referred to … Continue reading Asbestos Deaths in Italy Top 4,000 Per Year Decades After Ban »

HITOC for Mesothelioma: Benefits May Outweigh the Risk

HITOC for mesothelioma

The benefits of a localized chemotherapy regimen known as HITOC for mesothelioma outweigh the small risk of kidney failure for most patients.  That is the conclusion of a new study published in the journal Cancers. German researchers conducted a retrospective review of the medical literature on HITOC (also called HITHOC) in pleural mesothelioma patients.  They were most interested in patients who developed kidney problems after the procedure. This is a known risk with HITOC for mesothelioma. But the study suggests that most patients benefit from this type of chemotherapy in spite of the risk. Localized Treatment Versus Systemic Treatment Pleural mesothelioma tumors start on the membrane around the lungs and are hard to treat. Once this cancer takes hold, most … Continue reading HITOC for Mesothelioma: Benefits May Outweigh the Risk »

Second-Line Treatment with Ramucirumab Improves Mesothelioma Survival

second-line treatment with ramucirumab

New evidence suggests that second-line treatment with ramucirumab after first-line chemotherapy may lead to longer survival in people with pleural mesothelioma.  Researchers in Italy recently published results of a double-blind, placebo-controlled trial of the drug. Ramucirumab inhibits a protein mesothelioma tumors need to form new blood vessels.  The study included 161 pleural mesothelioma patients from across Italy. Researchers gave half of them second-line treatment with ramucirumab and another drug called gemcitabine. The other half had second-line treatment with gemcitabine alone.  Results showed the ramucirumab group lived more than six months longer than those who got only gemcitabine.  Few Options for Recurrent Mesothelioma Pleural mesothelioma is an aggressive cancer with few good treatment options. Most patients start with chemotherapy with Alimta. … Continue reading Second-Line Treatment with Ramucirumab Improves Mesothelioma Survival »

MRI Imaging May Be Superior to CT for Pleural Mesothelioma Diagnosis and Staging

MRI imaging

When it comes to diagnosing and monitoring treatment response in people with pleural mesothelioma, MRI imaging may be better than CT.  That is the message from a new Italian study published in the online medical journal Cancers.  RIght now, CT (computed tomography) is the most popular form of imaging for pleural mesothelioma. Cancer doctors use CT images to help diagnose mesothelioma. They also use it to see how widespread the cancer is and to find out if treatment is making a difference.  But radiology researchers at Pisa University Hospital say MRI imaging has advantages over CT for people with the rare asbestos cancer.  Mesothelioma Diagnosis and Prognosis  Malignant pleural mesothelioma is the most serious of several health conditions linked to … Continue reading MRI Imaging May Be Superior to CT for Pleural Mesothelioma Diagnosis and Staging »

Yervoy and Opdivo for Mesothelioma: Three Year Results Still Look Good

Yervoy and Opdivo for mesothelioma

Three years after the last patients enrolled in the clinical trial of Yervoy and Opdivo for mesothelioma, survival results still look promising for this immunotherapy treatment.  Researchers presented an update of the CheckMate 743 trial at the recent virtual conference of the European Society for Medical Oncology (ESMO). The team found that more than 23% of patients on Yervoy and Opdivo for mesothelioma were still alive at three years. Only 15% of the chemotherapy group were still living.  Immunotherapy for Malignant Mesothelioma Alimta (pemetrexed) was the first drug to receive FDA approval for mesothelioma chemotherapy. The FDA approved it in 2004.  Before Alimta, patients had even fewer options that they do today. Most mesothelioma patients now start treatment with a … Continue reading Yervoy and Opdivo for Mesothelioma: Three Year Results Still Look Good »

HITHOC for Pleural Mesothelioma: “Safe, Feasible and Effective”

HITHOC for pleural mesothelioma

A newly published study says a localized form of chemotherapy called HITHOC for pleural mesothelioma is “safe, feasible, and effective.” Researchers from Italy’s University of Pisa conducted the study. They did a thorough review of the medical literature on the procedure since 1994.  They conclude that HITHOC for pleural mesothelioma after surgery keeps tumors in check and improves survival. The downside is that there is not enough standardization in how doctors use the procedure.  How HITHOC for Pleural Mesothelioma Works HITHOC stands for hyperthermic intrathoracic chemotherapy. Standard mesothelioma chemotherapy enters the whole body at once through the bloodstream. That is one reason that many mesothelioma patients on chemotherapy have side effects like nausea and low white blood cell counts.  HITHOC … Continue reading HITHOC for Pleural Mesothelioma: “Safe, Feasible and Effective” »

Biomarkers in Pleural Effusions Can Improve Mesothelioma Diagnosis

biomarkers in pleural effusions

Italian scientists say some newly identified biomarkers in pleural effusions are very good at ruling out mesothelioma in patients who do not have the disease.  Unfortunately, most of these biomarkers are not as good as positively identifying mesothelioma. But their accuracy can be improved by combining several of them.  Pleural effusions are pockets of excess fluid that collect around the lungs of people with certain kinds of cancer and other conditions.  Mesothelioma biomarkers in pleural effusions are proteins and other substances that are mostly found in mesothelioma patients. The new study suggests that using these biomarkers the right way can lead to more accurate diagnoses. The Importance of Biomarkers in Pleural Effusions Pleural mesothelioma is a rare cancer of the … Continue reading Biomarkers in Pleural Effusions Can Improve Mesothelioma Diagnosis »

New Study: Pure Talc is Not a Cause of Pleural Mesothelioma

cause of pleural mesothelimoa

New research out of Italy is further evidence that asbestos – and not other dusty minerals like talc – is almost always the cause of pleural mesothelioma. The evidence comes from a 50-year study of more than 1,700 Northern Italian talc miners and millers.  Talc and asbestos often lie close together in the ground. Some people who have worked in talc mines or even used talc products have developed malignant mesothelioma. Many of these mines and products were contaminated with asbestos. This makes it difficult to know if it was the talc or the asbestos that caused the cancer.  But the workers in the new study worked in a mine that was uncontaminated with asbestos. Analysis of their causes of death … Continue reading New Study: Pure Talc is Not a Cause of Pleural Mesothelioma »

Get your free copy of
“Surviving Mesothelioma” Today!